Urogen Pharma (NASDAQ:URGN) Insider Sells $98,551.86 in Stock

Key Points

• Mark Schoenberg, an insider at Urogen Pharma, sold 5,149 shares at an average price of $19.14, totaling $98,551.86, reducing his ownership by 3.15% to 158,229 shares.
• Urogen Pharma's stock recently gained 1.7%, reaching $19.22, with significant trading volume of 1,159,647 shares.
• Analysts maintain a consensus rating of "Buy" for Urogen Pharma, with target prices ranging from $25.00 to $50.00.

Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 5,149 shares of the business's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $98,551.86. Following the completion of the sale, the insider owned 158,229 shares in the company, valued at $3,028,503.06. This represents a 3.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Mark Schoenberg also recently made the following trade(s):

• On Monday, June 9th, Mark Schoenberg sold 5,162 shares of Urogen Pharma stock. The stock was sold at an average price of $7.37, for a total value of $38,043.94.

Urogen Pharma Stock Performance

URGN stock traded up $0.34 on Friday, hitting $19.40. 1,007,990 shares of the company's stock were exchanged, compared to its average volume of 1,235,309. Urogen Pharma has a 12-month low of $3.42 and a 12-month high of $19.74. The firm has a 50 day moving average price of $12.52 and a two-hundred day moving average price of $11.03. The stock has a market cap of $896.28 million, a P/E ratio of -6.10 and a beta of 1.12.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. The business had revenue of $20.25 million for the quarter, compared to analysts' expectations of $22.71 million. Sell-side analysts expect that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Institutional Trading of Urogen Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. CWM LLC lifted its position in Urogen Pharma by 6,047.1% during the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock worth $58,000 after acquiring an additional 5,140 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Urogen Pharma during the 4th quarter worth about $59,000. Lazard Asset Management LLC acquired a new stake in Urogen Pharma during the 4th quarter worth about $67,000. GAMMA Investing LLC lifted its position in Urogen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock worth $83,000 after acquiring an additional 7,392 shares during the period. Finally, Aquatic Capital Management LLC acquired a new stake in Urogen Pharma during the 4th quarter worth about $101,000. Institutional investors and hedge funds own 91.29% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on URGN. The Goldman Sachs Group set a $16.00 price objective on Urogen Pharma and gave the company a "neutral" rating in a research report on Friday, June 13th. Guggenheim reissued a "buy" rating and set a $30.00 price target (up from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of Urogen Pharma in a report on Monday, July 7th. Finally, Oppenheimer set a $31.00 target price on Urogen Pharma and gave the company a "buy" rating in a research report on Friday, June 13th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $32.86.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.